Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DERM
JOURNEY MEDICAL CORPORATION
NASDAQ
$7.47
▼ DOWN 0.80% (-0.06)

KEY STATISTICS

Market Cap$205.59 M
52w High$9.55
52w Low$4.31
Dividend Yield—
Frequency—
P/E-20.19
Volume122.96K
Shares Out.27.52M

COMPANY

LEADERSHIP

Claude Maraoui
CHIEF EXECUTIVE
Claude Maraoui

COMPENSATION 2026

Salary$583,495
Stock Awards$310,938
Incentive Plan Pay$352,735
All Other Comp.$14,000
Total$1,665,876

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 12, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
58

PRICE TARGET

Target High$13.00
Target Low$10.50
Target Median$11.75
Target Consensus$11.75

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$21.89M
NOV
11
WED

PRICE

$7.47 ▼ DOWN 0.80% (−$0.06)
$7.42$7.50$7.589:32 AM10:37 AM11:41 AM12:45 PM1:50 PM2:55 PM3:59 PM7.47

About Journey Medical Corporation

https://journeymedicalcorp.com ↗

Journey Medical Corporation develops and commercializes dermatology pharmaceuticals in the U.S., including treatments for hyperhidrosis, acne, and fungal conditions, with a portfolio of branded and generic products.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT JOURNEY MEDICAL CORPORATION IS KNOWN FOR

EMROSI™ (Minocycline Hydrochloride Modified-Release Capsules, 40 mg)
EMROSI™ (Minocycline Hydrochloride Modified-Release Capsules, 40 mg)

EMROSI™, FDA-approved in November 2024, is a prescription oral medication for adult rosacea inflammatory lesions and a key growth driver for Journey Medical’s innovative dermatology portfolio.

COMPETITORS

COMPETITOR
ARQT COMPARE
BFRI COMPARE
DRMA COMPARE
FBIO COMPARE
SLGL COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Qbrexza$7.36M $5.54M ▼$5.03M ▼$5.11M ▲
Accutane$2.77M $3.06M ▲$3.31M ▲$3.36M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
4
RANKED BY POSITION SIZE
VTS.AX
0.00% · 470.4K
IWC
0.03% · 51.6K
QQQS
0.58% · 17.7K
DFMC
0.00% · 3.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
41.66%
HOLDERS
115
TOP 12 OF 115 · RANKED BY POSITION SIZE
Wasatch Advisors LP
2.9M sh · $20.24M
Tang Capital Management LLC
1.9M sh · $14.3M
Opaleye Management Inc.
975.0K sh · $7.52M
Blackrock, Inc.
972.9K sh · $4.56M
B. Riley Securities, Inc.
864.7K sh · $1.66M
J. Goldman & Co LP
798.4K sh · $6.16M
Vanguard Group Inc
764.1K sh · $5.89M
Punch & Associates Investment Management, Inc.
536.0K sh · $3.79M
Pale Fire Capital Se
528.6K sh · $3.74M
Geode Capital Management, LLC
463.2K sh · $2.17M
Millennium Management LLC
457.8K sh · $3.53M
Summit Financial, LLC
390.4K sh · $3.01M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Toledano Miranda Jayne
Purchase · 50.0K shares
2026-07-01
★
DIRECTOR
Smith Justin Adam
Purchase · 50.0K shares
2026-07-01
★
DIRECTOR
Herskowitz Neil
Purchase · 50.0K shares
2026-07-01
★
DIRECTOR
Toledano Miranda Jayne
Purchase · 10.0K shares
2026-06-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
FENC$12.27COMPARE
OBIO$5.18COMPARE
RNAC$9.60COMPARE
OSUR$3.60COMPARE
IVA$4.71COMPARE
OGI$1.22COMPARE
MDWD$12.66COMPARE
NYXH$1.60COMPARE